Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,211–1,220 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1211
- Medicine slug
- pindolol
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
2 L/kg
- Numeric value
- 2
- Unit
- L/kg
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0daed7b3-6017-4611-8c3a-2f390470f8bc (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b331a73f-bf7b-4442-8901-36d016530279 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79a8d97b-9461-4914-bcbb-f6f64a39e5e7 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:611be921-e9b6-4800-80b2-c2d4f677cdb2 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f91e5715-e37d-45fa-97a7-4d32fbd51060 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efdb0189-37b5-45d6-b92c-1157bb9df789 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f529ff35-f82b-4a3a-96b4-096bfc8e81b5 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1049edf-376e-317b-e053-2995a90a2aac (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fb36f8f-11fe-498e-8667-daeccf8b2273 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b95e96-ead9-4149-badb-7d33077e82ec (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8498aead-0aef-4cd8-a191-05cae57a55e5 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The volume of distribution in healthy subjects is about 2 L/kg.
Projected row 1212
- Medicine slug
- pioglitazone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 41
- Agreement rate
- 1
- Recorded readings
8.3 hours
- Numeric value
- 8.3
- Unit
- hours
- Source records
- 41
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 41 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e8d5a3-b0da-1d70-e053-2a95a90aa435 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see DOSAGE AND ADMINISTRATION (2.3) and DRUG INTERACTIONS (7.1)] § Indicates duration of concomitant administration with highest
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbdaaa34-06c4-49af-85b4-91a85922b30b (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ymbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in Cmax Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑ 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [ see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7 ) ] ↑ 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a9f6777-9b4f-482a-aa4e-4900f9d35b8e (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
rug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3)and Drug Interactions (7.1)] §Indicates duration of concomitant administration with highest t
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0846e3e-68b2-fd55-e053-2995a90a673e (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b5506c4-8cc2-44fb-ba2b-0e29fb73943d (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
drug and no change =1 fold ) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓indicate the exposure increase and decrease, respectively ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7.1 )] § Indicates duration of concomitant administration with hig
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fe57786-5c7d-4b11-8fb4-de341e2e5128 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
drug and no change =1 fold ) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓indicate the exposure increase and decrease, respectively ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7.1 )] § Indicates duration of concomitant administration with hig
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:482cef76-0623-4b4f-a0ea-f008c97b2281 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
drug and no change =1 fold ) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓indicate the exposure increase and decrease, respectively ‡The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7.1 )] §Indicates duration of concomitant administration with high
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5ac747-991f-30e4-e053-2a95a90a4780 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2ddc491-88a9-4063-9150-443b4fa4330c (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ymbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in C max Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] ↑6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 mg
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:060e3169-46a7-419d-9acc-05586cb2406b (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see and ] § Indicates duration of concomitant administration with highest twice-daily dose of topiramate from Day 14 onwards ove
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6397fb4c-081b-4abd-ab4b-0a3fbf99e663 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f725cdaf-fc7a-40d6-ba64-1dccd1b25d7a (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bde7fa79-aafc-3ba0-e053-2a95a90aa4d2 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ymbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in Cmax Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑ 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [ see Dosage and Administration ( 2.3) and Drug Interactions ( 7) ] ↑ 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 m
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f9b2d8-3e78-4e2f-bcf1-d00595078fa1 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
rug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3)and Drug Interactions (7.1)] §Indicates duration of concomitant administration with highest t
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1112e4b-e9d5-13c3-e053-2995a90a6d0a (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4751cb4-0700-dd22-e053-2995a90adfdb (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ymbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in Cmax Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑ 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [ see Dosage and Administration ( 2.3) and Drug Interactions ( 7) ] ↑ 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 m
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04577c39-a9c0-4c66-a775-4c79e2c3dea5 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
rug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3)and Drug Interactions (7.1)] §Indicates duration of concomitant administration with highest t
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4483b1c6-7095-4a63-8128-ac2d91e11040 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:164c444c-7c56-4482-9cbd-0e0f0ad30c44 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see and ] § Indicates duration of concomitant administration with highest twice-daily dose of topiramate from Day 14 onwards ove
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9548800-4c44-473d-a89b-c705484548b3 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f434ba0d-13f3-42ae-a2d5-cddb93fde1e8 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:475c4f39-dd2a-48f9-a07c-9344bbda58a9 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
drug and no change =1 fold ) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓indicate the exposure increase and decrease, respectively ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7.1 )] § Indicates duration of concomitant administration with hig
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cd7c8b7-f5d4-423b-ae9f-86541869d8cf (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d740d2a2-b26d-4b16-aedc-e4b4b1c94daa (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
%); symbols of and indicate the exposure increase and decrease, respectively Change in C max Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 mg 3
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31619517-a590-408a-ae9e-76c99f0a0a1d (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
%); symbols of and indicate the exposure increase and decrease, respectively Change in C max Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 mg 3
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:699e865a-952e-459e-a871-9b7cce475b71 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b77dbeb-61d1-4df3-872b-2f4f75a110db (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
rug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7.1 )] § Indicates duration of concomitant administration with hig
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22569835-bc9f-7787-e063-6394a90a6232 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ymbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in Cmax Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑ 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [ see Dosage and Administration ( 2.3) and Drug Interactions ( 7) ] ↑ 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 m
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af863b9e-9646-3b1e-e053-2995a90ab93a (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
drug and no change =1 fold ) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓indicate the exposure increase and decrease, respectively ‡The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1)] §Indicates duration of concomitant administration with highest
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6cad01e-cd65-4c8d-9e49-399404f22005 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f259863-21fd-4d62-b094-4eff845944df (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64b46e5-3c94-4635-908e-cdc2263bd3d4 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0331400c-b163-4856-bfb0-965470247cb3 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5c81c67-90cf-4e64-acb5-58b0358fa742 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ymbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in Cmax Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑ 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [ see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7 ) ] ↑ 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3a2222d-5156-4533-bb4b-74652c8eb9c7 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
mbols of ↑ and ↓ indicate the exposure increase and decrease, respectively Change in C max Gemfibrozil 600 mg twice daily for 2 days (N = 12) 15 mg single dose ↑ 3.2-fold The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7)] ↑ 6% Ketoconazole 200 mg twice daily for 7 days (N = 28) 45 mg ↑
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29073b0a-1d7e-4354-87c7-e764106978d8 (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:692e662a-3b31-42c3-a075-42abe44c74db (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
drug and no change =1 fold ) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓indicate the exposure increase and decrease, respectively ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration ( 2.3 ) and Drug Interactions ( 7.1 )] § Indicates duration of concomitant administration with hig
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f844e44-0f0d-4b28-9d34-b97780e1c6ec (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41a9586c-8768-4fc3-bb78-e6d98b09030b (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:466ef4c8-84d4-4ded-8505-a33f12adf31c (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72b46a1e-d9ea-4a47-95ef-5eae96ef1e7f (opens source in a new tab)
Pioglitazone label
Version not recorded · Effective date not recorded
ug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively. ‡ The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [see Dosage and Administration (2.3) and Drug Interactions (7.1) ] § Indicates duration of concomitant administration with highes
Projected row 1213
- Medicine slug
- pirfenidone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 35
- Source count
- 35
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 35
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 35 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:155b948e-47f5-4741-8e82-2ed65ccfab7d (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9214862e-9ef7-4370-856a-f5697978270a (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7f3485e-9dcc-45db-9b9c-74c70e22c4bb (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ccfe91e-d1fc-d4c1-115b-dd7859b2c3e6 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3115f15f-171c-4266-8dc8-5655f56e6acc (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination : The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e4f991a-c9e3-4121-97d0-d07954f17336 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94362a07-7c64-42ce-adef-f49585af55d6 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfcb3157-cfa1-493d-9598-1e7fd3d355d9 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f5f7cc9-394e-4da0-87eb-84cfff9707a3 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd3483bf-96e9-4d6b-a844-63bd002c48a4 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d0eee8c-dc7d-4444-8684-e9c9335291c8 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination : The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fab59395-1c5d-4c64-ba47-34d75736e983 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbbd14a4-b7e6-4147-9314-bb715dfb1a51 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fbdb556-b164-4e0b-a95e-6004d50e3364 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81f17f7d-cb04-4052-8682-dd3e330210ab (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50958060-c904-4374-997d-59df54007fa4 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination : The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:976620bb-c10e-4b13-8a97-7025fda6b7d5 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1abc06c7-6a45-4a0b-b2da-c228aaa137ed (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73db516f-8c80-431f-8190-33081718cf8d (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination : The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:741d1b9c-e281-4eca-b327-e25e82313006 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination : The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1927bf5d-1ef3-4a36-8dac-dc0a45b72fec (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a235768d-d26d-4ded-ae75-53e93310ff6a (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4d7aa2-1248-4639-baf5-5e2ae72cbcd8 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ff87b3-0a88-15b4-e063-6294a90a72ab (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1709582c-9975-4dc1-8181-2501ee670eef (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16fca4fc-b641-4ee8-a2ee-a35189ce1f3b (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:945d4337-7d18-4d84-807b-8ae13750c76d (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f1ca21-4c08-4103-889d-1d9c929b5fad (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08046b49-a8b3-a78d-e063-6394a90a80fa (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea26490e-fd32-4807-8556-eb6f5f963c23 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bdc7ed9-e51c-4101-a792-31619f05136b (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29b0fd0e-5a2b-4da7-8524-177dc28bf55e (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b3261fe-c066-6e86-e063-6294a90a675c (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c171e4af-1619-4712-958f-ef96adfede37 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Elimination: The mean terminal half-life is approximately 3 hours in healthy subjects.
Projected row 1214
- Medicine slug
- pirfenidone
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 35
- Source count
- 35
- Agreement rate
- 0.971429
- Recorded readings
59 to 71 liters
- Numeric value
- 59
- Unit
- L
- Source records
- 34
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 34 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:155b948e-47f5-4741-8e82-2ed65ccfab7d (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9214862e-9ef7-4370-856a-f5697978270a (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7f3485e-9dcc-45db-9b9c-74c70e22c4bb (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ccfe91e-d1fc-d4c1-115b-dd7859b2c3e6 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3115f15f-171c-4266-8dc8-5655f56e6acc (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e4f991a-c9e3-4121-97d0-d07954f17336 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfcb3157-cfa1-493d-9598-1e7fd3d355d9 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f5f7cc9-394e-4da0-87eb-84cfff9707a3 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd3483bf-96e9-4d6b-a844-63bd002c48a4 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d0eee8c-dc7d-4444-8684-e9c9335291c8 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fab59395-1c5d-4c64-ba47-34d75736e983 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbbd14a4-b7e6-4147-9314-bb715dfb1a51 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fbdb556-b164-4e0b-a95e-6004d50e3364 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81f17f7d-cb04-4052-8682-dd3e330210ab (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50958060-c904-4374-997d-59df54007fa4 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:976620bb-c10e-4b13-8a97-7025fda6b7d5 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1abc06c7-6a45-4a0b-b2da-c228aaa137ed (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73db516f-8c80-431f-8190-33081718cf8d (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:741d1b9c-e281-4eca-b327-e25e82313006 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1927bf5d-1ef3-4a36-8dac-dc0a45b72fec (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a235768d-d26d-4ded-ae75-53e93310ff6a (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4d7aa2-1248-4639-baf5-5e2ae72cbcd8 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ff87b3-0a88-15b4-e063-6294a90a72ab (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1709582c-9975-4dc1-8181-2501ee670eef (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16fca4fc-b641-4ee8-a2ee-a35189ce1f3b (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:945d4337-7d18-4d84-807b-8ae13750c76d (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f1ca21-4c08-4103-889d-1d9c929b5fad (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08046b49-a8b3-a78d-e063-6394a90a80fa (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea26490e-fd32-4807-8556-eb6f5f963c23 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bdc7ed9-e51c-4101-a792-31619f05136b (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29b0fd0e-5a2b-4da7-8524-177dc28bf55e (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b3261fe-c066-6e86-e063-6294a90a675c (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c171e4af-1619-4712-958f-ef96adfede37 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 to 71 liters.
59 liters
- Numeric value
- 59
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94362a07-7c64-42ce-adef-f49585af55d6 (opens source in a new tab)
Pirfenidone label
Version not recorded · Effective date not recorded
Mean apparent oral volume of distribution is approximately 59 liters to 71 liters.
Projected row 1215
- Medicine slug
- piroxicam
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
50 hours
- Numeric value
- 50
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1123fe1-b79c-430b-8548-08cd6e518482 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ee820e4-a479-4b7d-8730-101ac1f8015c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:923a81d7-78e7-48e9-901d-e3ce3539aba3 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cd10ca2-f0a5-4b3a-bc5f-e25aba1f903c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23972bf0-e5b8-4f4b-97d0-caa05d6b061c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b48a1615-23b5-4db7-bb96-cec551d227f6 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69631088-2645-4cc9-9c64-a36111ab5d21 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6039e036-c0aa-4249-af50-115f49ad758a (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b8eb243-0efb-4777-b627-b7ae042f8823 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99351f77-46b8-4741-9193-1a6d6a7b0b18 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0373da3a-7779-4e26-87f1-cd346018282c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf53d94d-9808-44c0-a01b-a08975bc6e21 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9684cb2-76f3-4c1b-b9e5-1f8fe55f3695 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6335245-7e04-46b9-a505-f47647781e19 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f5ea9e8-3942-4e84-b237-c38517a97a8e (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa56b439-893d-003e-e053-6294a90a865b (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ea6042e-0090-df18-e063-6394a90a0a0a (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
The prolonged half-life (50 hours) results in the maintenance of relatively stable plasma concentrations throughout the day on once daily doses and significant accumulation upon multiple dosing.
Projected row 1216
- Medicine slug
- piroxicam
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
0.14 L/kg
- Numeric value
- 0.14
- Unit
- L/kg
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1123fe1-b79c-430b-8548-08cd6e518482 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ee820e4-a479-4b7d-8730-101ac1f8015c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:923a81d7-78e7-48e9-901d-e3ce3539aba3 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cd10ca2-f0a5-4b3a-bc5f-e25aba1f903c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23972bf0-e5b8-4f4b-97d0-caa05d6b061c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b48a1615-23b5-4db7-bb96-cec551d227f6 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69631088-2645-4cc9-9c64-a36111ab5d21 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6039e036-c0aa-4249-af50-115f49ad758a (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b8eb243-0efb-4777-b627-b7ae042f8823 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99351f77-46b8-4741-9193-1a6d6a7b0b18 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0373da3a-7779-4e26-87f1-cd346018282c (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf53d94d-9808-44c0-a01b-a08975bc6e21 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9684cb2-76f3-4c1b-b9e5-1f8fe55f3695 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6335245-7e04-46b9-a505-f47647781e19 (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f5ea9e8-3942-4e84-b237-c38517a97a8e (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa56b439-893d-003e-e053-6294a90a865b (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ea6042e-0090-df18-e063-6394a90a0a0a (opens source in a new tab)
Piroxicam label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of piroxicam is approximately 0.14 L/kg.
Projected row 1217
- Medicine slug
- pitavastatin
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
51%
- Numeric value
- 51
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a52401eb-a822-475b-a40d-7b8acde2ae1a (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9622824-cee5-49d7-9273-f18b9cc176fd (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29ea90c-f4e5-4f14-9660-a0404ef87f18 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44dcbf97-99ec-427c-ba50-207e0069d6d2 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fbfcc0c-9251-456d-a525-e62cfd8abd4b (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35e747e-10ac-4a76-bce6-187618fc64f9 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad1ecb9-822d-47c1-9f6f-6f771fa0f924 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98e3f1df-5b38-4169-a340-adb145eac459 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26b5e5e8-45cd-4a98-9af4-2d04c1130881 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac09182-dcf2-1770-e053-6394a90af50c (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f11ee80-871e-4f13-e063-6394a90af19d (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d5a1b78-4aa6-537b-e063-6394a90a522f (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of pitavastatin oral solution is 51%.
Projected row 1218
- Medicine slug
- pitavastatin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
12 hours
- Numeric value
- 12
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a52401eb-a822-475b-a40d-7b8acde2ae1a (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9622824-cee5-49d7-9273-f18b9cc176fd (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29ea90c-f4e5-4f14-9660-a0404ef87f18 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44dcbf97-99ec-427c-ba50-207e0069d6d2 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fbfcc0c-9251-456d-a525-e62cfd8abd4b (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35e747e-10ac-4a76-bce6-187618fc64f9 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad1ecb9-822d-47c1-9f6f-6f771fa0f924 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98e3f1df-5b38-4169-a340-adb145eac459 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26b5e5e8-45cd-4a98-9af4-2d04c1130881 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac09182-dcf2-1770-e053-6394a90af50c (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f11ee80-871e-4f13-e063-6394a90af19d (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d5a1b78-4aa6-537b-e063-6394a90a522f (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is approximately 12 hours.
Projected row 1219
- Medicine slug
- pitavastatin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a52401eb-a822-475b-a40d-7b8acde2ae1a (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9622824-cee5-49d7-9273-f18b9cc176fd (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29ea90c-f4e5-4f14-9660-a0404ef87f18 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44dcbf97-99ec-427c-ba50-207e0069d6d2 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fbfcc0c-9251-456d-a525-e62cfd8abd4b (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35e747e-10ac-4a76-bce6-187618fc64f9 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad1ecb9-822d-47c1-9f6f-6f771fa0f924 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98e3f1df-5b38-4169-a340-adb145eac459 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26b5e5e8-45cd-4a98-9af4-2d04c1130881 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac09182-dcf2-1770-e053-6394a90af50c (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
prolongation of the QTc interval or heart rate at daily doses up to 16 mg (4 times the recommended maximum dose of 4 mg daily). 12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f11ee80-871e-4f13-e063-6394a90af19d (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
prolongation of the QTc interval or heart rate at daily doses up to 16 mg (4 times the recommended maximum dose of 4 mg daily). 12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d5a1b78-4aa6-537b-e063-6394a90a522f (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
Projected row 1220
- Medicine slug
- pitavastatin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
148 L
- Numeric value
- 148
- Unit
- L
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a52401eb-a822-475b-a40d-7b8acde2ae1a (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9622824-cee5-49d7-9273-f18b9cc176fd (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29ea90c-f4e5-4f14-9660-a0404ef87f18 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44dcbf97-99ec-427c-ba50-207e0069d6d2 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fbfcc0c-9251-456d-a525-e62cfd8abd4b (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35e747e-10ac-4a76-bce6-187618fc64f9 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad1ecb9-822d-47c1-9f6f-6f771fa0f924 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98e3f1df-5b38-4169-a340-adb145eac459 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26b5e5e8-45cd-4a98-9af4-2d04c1130881 (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac09182-dcf2-1770-e053-6394a90af50c (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f11ee80-871e-4f13-e063-6394a90af19d (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d5a1b78-4aa6-537b-e063-6394a90a522f (opens source in a new tab)
Pitavastatin label
Version not recorded · Effective date not recorded
Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1210Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.